Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Ultragenyx Pharmaceutical
Develops therapeutics for rare diseases

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases.

Its product includes Mepsevii and Crysvita.

The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Number of employees : 520 people.
Sales per Businesses
20162017Delta
USD (in Million)%USD (in Million)%
Rare Diseases Treatment Products0.133100%---
Collaboration and License--2.1481.8%-
Product--0.47618.2%-
Sales per Regions
20162017Delta
USD (in Million)%USD (in Million)%
United States0.133100%2.61100% +1863.91%
Managers
NameAgeSinceTitle
Emil D. Kakkis MD, PhD572010President, Chief Executive Officer & Director
Daniel G. Welch, MBA602015Non-Executive Chairman
Wladimir Hogenhuis-2018Chief Operating Officer
Shalini Sharp, MBA432012Chief Financial Officer & Executive Vice President
Dennis Karl Huang532015Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian, MD652018Chief Medical Officer & Executive Vice President
Eric Crombez, MD-2017Chief Medical Officer
William E. Aliski702011Independent Director
Matthew K. Fust, MBA532014Independent Director
Clay B. Siegall, PhD572014Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 50,182,357 46,929,707 93.5% 0 0.0% 93.5%
Shareholders
NameEquities%
Wellington Management Co. LLP 6,090,143 12.1%
Capital Research & Management Co. (Global Investors) 5,755,563 11.5%
The Vanguard Group, Inc. 3,976,375 7.92%
Capital Research & Management Co. (International Investors) 3,604,764 7.18%
BlackRock Fund Advisors 3,449,796 6.87%
Fidelity Management & Research Co. 3,441,112 6.86%
Emil D. Kakkis MD, PhD 3,010,213 6.00%
T. Rowe Price Associates, Inc. 2,796,392 5.57%
SSgA Funds Management, Inc. 1,648,751 3.29%
Columbia Wanger Asset Management LLC 1,291,107 2.57%
Company contact information
Ultragenyx Pharmaceutical, Inc.
60 Leveroni Court
Novato, CA 94949

Phone : +1.415.483.8800
Fax : +1.415.483.8810
Web : http://www.ultragenyx.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC33.23%3 219
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222
GENMAB-11.78%8 841
BLUEBIRD BIO INC-29.94%6 615
BIOCON LTD16.63%5 203
LOXO ONCOLOGY INC88.48%5 104
EXELIXIS, INC.-47.70%4 924
PEPTIDREAM INC12.34%4 814
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.-33.64%4 441
HUALAN BIOLOGICAL ENGINEERING INC--.--%4 370
NOVOCURE LTD118.37%4 184
AGIOS PHARMACEUTICALS INC14.76%3 875
ARRAY BIOPHARMA INC7.50%3 292
MADRIGAL PHARMACEUTICALS INC106.10%3 057
ARGEN-X20.34%3 027
INTERCEPT PHARMACEUTICALS INC73.79%2 940
ASCENDIS PHARMA A/S47.53%2 775
Connections : Ultragenyx Pharmaceutical
Sofinnova Ventures, Inc.
Global Alliance for TB Drug Development
TB Alliance
American Society of Nephrology
Everylife Foundation for Rare Diseases
Blackthorn Therapeutics, Inc.
Washington Roundtable
Emil Kakkis & Jenny Soriano Living Trust
Dimension Therapeutics, Inc.
Washington Biotechnology & Biomedical Association
Bonti, Inc.
American Society of Clinical Oncology
Biotechnology Innovation Organization
American Society of Hematology
The Pacific Northwest Research Institute, Inc.
© 2018 People , Fundamentals and Ownership